Vaxcyte (PCVX) Non-Current Deffered Revenue (2019 - 2020)
Vaxcyte (PCVX) posted quarterly Non-Current Deffered Revenue of $10000.0 for Q4 2020, down 41.18% year-over-year from $17000.0 in Q1 2020, and up 900.0% quarter-over-quarter from $1000.0 in Q3 2020.
Powered by 
Analysis
Vaxcyte (PCVX) Non-Current Deffered Revenue (2019 - 2020) Analysis & Trends
Vaxcyte (PCVX) has reported Non-Current Deffered Revenue for 2 consecutive years, with $10000.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Non-Current Deffered Revenue fell 41.18% year-over-year to $10000.0; the TTM figure through Dec 2020 stood at $10000.0 (down 41.18% YoY), while the FY2020 annual figure was $10000.0, down 41.18% from the prior year.
- Non-Current Deffered Revenue climbed to $10000.0 in Q4 2020 per PCVX's latest filing, from $1000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $17000.0 in Q4 2019 and bottomed at $1000.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Vaxcyte | 8.83 Bn | 8.83 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 10,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Jun 30, 2020 | 8,000.00 |
| Dec 31, 2019 | 17,000.00 |